These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 22713953

  • 1. Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphyloccus aureus.
    Bakar NS, Zin NM, Basri DF.
    Pak J Pharm Sci; 2012 Jul; 25(3):633-8. PubMed ID: 22713953
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
    Dilworth TJ, Sliwinski J, Ryan K, Dodd M, Mercier RC.
    Antimicrob Agents Chemother; 2014 Jul; 58(2):1028-33. PubMed ID: 24277036
    [Abstract] [Full Text] [Related]

  • 3. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G, White R, Friedrich L.
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [Abstract] [Full Text] [Related]

  • 4. Effect of sub-lethal doses of vancomycin and oxacillin on biofilm formation by vancomycin intermediate resistant Staphylococcus aureus.
    Mirani ZA, Jamil N.
    J Basic Microbiol; 2011 Apr; 51(2):191-5. PubMed ID: 20967790
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains.
    Miranda-Novales G, Leaños-Miranda BE, Vilchis-Pérez M, Solórzano-Santos F.
    Ann Clin Microbiol Antimicrob; 2006 Oct 12; 5():25. PubMed ID: 17034644
    [Abstract] [Full Text] [Related]

  • 6. Synergistic effects between silibinin and antibiotics on methicillin-resistant Staphylococcus aureus isolated from clinical specimens.
    Kang HK, Kim HY, Cha JD.
    Biotechnol J; 2011 Nov 12; 6(11):1397-408. PubMed ID: 21491604
    [Abstract] [Full Text] [Related]

  • 7. Cleistochlamys kirkii chemical constituents: Antibacterial activity and synergistic effects against resistant Staphylococcus aureus strains.
    Pereira F, Madureira AM, Sancha S, Mulhovo S, Luo X, Duarte A, Ferreira MJ.
    J Ethnopharmacol; 2016 Feb 03; 178():180-7. PubMed ID: 26674158
    [Abstract] [Full Text] [Related]

  • 8. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M, Aguilar L, Sevillano D, Giménez MJ, Alou L, González N, Cafini F, Cleeland R, Prieto J.
    Int J Antimicrob Agents; 2011 Apr 03; 37(4):332-8. PubMed ID: 21388792
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
    J Antimicrob Chemother; 2006 Dec 03; 58(6):1177-84. PubMed ID: 17062609
    [Abstract] [Full Text] [Related]

  • 12. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C, Leonard SN, Rybak MJ.
    Int J Antimicrob Agents; 2010 Jun 03; 35(6):527-30. PubMed ID: 20346632
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
    Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV.
    Int J Antimicrob Agents; 2011 Jun 03; 37(6):558-61. PubMed ID: 21497067
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA).
    Tang HJ, Chen CC, Ko WC, Yu WL, Chiang SR, Chuang YC.
    Int J Antimicrob Agents; 2011 Jul 03; 38(1):46-51. PubMed ID: 21549575
    [Abstract] [Full Text] [Related]

  • 17. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.
    Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, Pogliano J, Rybak MJ.
    Antimicrob Agents Chemother; 2013 May 03; 57(5):2376-9. PubMed ID: 23422917
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The synergistic effect of PDT and oxacillin on clinical isolates of Staphylococcus aureus.
    Iluz N, Maor Y, Keller N, Malik Z.
    Lasers Surg Med; 2018 Jul 03; 50(5):535-551. PubMed ID: 29333608
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.